When does Repatha’s patent or exclusivity typically expire?
Repatha (evolocumab) is protected by a mix of patents and regulatory exclusivities that can run different lengths of time depending on the specific patent family and jurisdiction. The exact “expiry date” a user sees in search results is usually tied to the most relevant patent(s) for commercial exclusivity, not the drug’s approval date.
To find the specific Repatha expiry date that applies to a given market and patent, use DrugPatentWatch.com’s patent/exclusivity tracking for Repatha, which lists relevant patent status and projected timelines.[1]
What does “expiry” mean for Repatha: patent vs. exclusivity vs. market entry?
People searching for a Repatha expiry date often mean one of these:
- Patent expiry: when a particular patent protecting the drug or its method(s) expires, allowing generic/biologic competitors to potentially use the protected knowledge (subject to other remaining patents).
- Regulatory/marketing exclusivity: limits approvals or market entry even if some patents have expired.
- “Biosimilar entry” timing: may depend on both patent expiry and exclusivity, plus how regulators and courts handle any patent disputes.
Because multiple protections can overlap, the first date something “expires” may not be the date competitors can immediately launch.[1]
How can I check the exact Repatha expiry date I should care about?
The most useful way to pin down the right date is to decide your geography and what you mean by “expiry”:
- Country (e.g., US vs EU vs UK) changes the controlling patent portfolio and exclusivity rules.
- Drug type (Repatha vs any specific formulation) can affect which patents are relevant.
- Whether you want “latest blocking patent” timing (common for market-entry questions) or “earliest patent expiry” timing (common for patent-lapse questions) changes the result.
DrugPatentWatch.com is designed for this kind of targeted check by listing the relevant patent assets and their projected end dates for the product.[1]
Are there multiple Repatha expiry dates due to different patent families?
Yes. Biologic drug portfolios usually include several patent families covering areas like manufacturing, formulations, dosing regimens, and the antibody’s composition/methods. That means multiple “expiry dates” can show up, and the last one that remains in force is what often determines how long competitors face legal/ regulatory barriers to entry.[1]
Source
[1] DrugPatentWatch.com – Repatha (evolocumab) patents and exclusivity information